Spotlight on fluvoxamine in anxiety disorders in children and adolescents

CNS Drugs

Volumn 16, Issue 2, 2002, Pages 139-144

  Cheer, Susan M ^a   Figgitt, David P ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; FLUVOXAMINE; SEROTONIN UPTAKE INHIBITOR; THEOPHYLLINE; WARFARIN;

ADOLESCENT; ADULT; ANXIETY NEUROSIS; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG EXCRETION; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; HUMAN; OBSESSION; PRIORITY JOURNAL; REVIEW; SEPARATION ANXIETY; SOCIAL PHOBIA; STEADY STATE;

EID: 0036174731     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200216020-00006     Document Type: Review

References (48)

1. Review of the animal pharmacology and pharmacokinetics of fluvoxamine
2. Serotonin-selective antidepressants
3. Fluvoxamine, a specific 5-hydroxytryptamine uptake inhibitor
4. Antidepressants and serotonin neurons of the raphe
5. Effects of monoamine uptake inhibitors on extracellular and platelet 5-hydroxytryptamine in rat blood: Different effects of clomipramine and fluoxetine
6. Fluvoxamine preferentially increases extracellular 5-hydroxytryptamine in the raphe nuclei: An in vivo microdialysis study
7. Fluvoxamine: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness
8. Acute effects of atypical antidepressants on various receptors in the rat brain
9. Antagonism by antidepressants of neurotransmitter receptors of normal human brain in vitro
10. [3H]8-OH-DPAT labels the 5-hydroxytryptamine uptake recognition site and the 5-HT1A binding site in the rat striatum
11. Evidence for a role of 5-HT1C receptors in the antiserotonergic properties of some antidepressant drugs
12. Fluoxetine and two other serotonin reuptake inhibitors without affinity for neuronal receptors
13. The effect of anti-depressants on aversive periaqueductal gray stimulation in rats
14. Preclinical evidence on the psychotrophic profile of fluvoxamine
15. Effects of 5-HT uptake inhibitors, agonists and antagonists on burying of harmless objects by mice; a putative test for anxiolytic agents
16. Selective serotonin reuptake inhibitors decrease schedule-induced polydipsia in rats: A potential model for obsessive compulsive disorder
17. A double-blind placebo-controlled study to compare the autonomic effects of fluvoxamine with those of amitriptyline and doxepin in healthy volunteers
18. A placebo controlled study of the cardiovascular effects of fluvoxamine and clovoxamine in human volunteers
19. Cardiovascular effects of fluvoxamine and maprotiline in depressed patients
20. Electrocardiographic findings during extended clinical trials of fluvoxamine in depression: One years experience
21. Cardiovascular effects of imipramine, fluvoxamine, and placebo in depressed out-patients
22. Comparison of the (pro) convulsive properties of fluvoxamine and clomipramine with eight other antidepressants in an animal model
23. A comparison of the effects of fluvoxamine and amitriptyline on autonomic functions in healthy volunteers
24. Pharmaco-EEg profiles of antidepressants. Pharmacodynamic studies with fluvoxamine
25. Effects of fluvoxamine, alone and in combination with ethanol, on psychomotor and cognitive performance and on autonomic nervous system reactivity in healthy volunteers
26. Overview of the pharmacokinetics of fluvoxamine
27. Non-linear fluvoxamine disposition
28. Nonlinear pharmacokinetics of fluvoxamine and gender differences
29. Fluoxetine: A review of its use in anxiety disorders and mixed anxiety and depression
30. Clinical pharmacokinetics of fluvoxamine: Applications to dosage regimen design
31. Fluvoxamine: An overview of its pharmacological properties and review of its therapeutic potential in non-depressive disorders
32. The multiple-dose pharmacokinetics of fluvoxamine in children and adolescents
33. The multiple-dose pharmacokinetics of fluvoxamine maleate in children and adolescents
34. Fluvoxamine inhibits the CYP2C19-catalyzed bioactivation of chloroguanide
35. Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine
36. In vivo inhibition of CYP2C19 but not CYP2D6 by fluvoxamine
37. A pharmacokinetic and pharmacodynamic evaluation of the combined administration of alprazolam and fluvoxamine
38. Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: Comparison with other selective serotonin reuptake inhibitor antidepressants
39. Distinction of CYP1A1 and CYP1A2 activity by selective inhibition using fluvoxamine and isosafrole
40. Fluvoxamine is a potent inhibitor of cytochrome P4501A2
41. Selective serotonin reuptake inhibitors and theophylline metabolism in human liver microsomes: Potent inhibition by fluvoxamine
42. Fluvoxamine: An updated review of its use in the management of adults with anxiety disorders
43. Fluvoxamine for children and adolescents with obsessive-compulsive disorder: A randomized, controlled, multicenter trial
44. Fluvoxamine open-label treatment of adolescent inpatients with obsessive- compulsive disorder or depression
45. Fluvoxamine in adolescents with obsessive-compulsive disorder
46. Fluvoxamine in childhood OCD: Long-term treatment
47. Fluvoxamme for the treatment of anxiety disorders in children and adolescents